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Abstract
While chronic lung disease causes substantial global morbidity and mortality, global estimates have primarily
been based on broad assumptions. Specific country data from low-income countries such as Nepal are limited.
This review assessed primary evidence on chronic respiratory disease burden among adults in Nepal.
A systematic search was performed in June 2019 (updated May 2020) for studies through nine databases.
High levels of heterogeneity deemed a narrative synthesis appropriate. Among 27 eligible studies identified,
most were low-moderate quality with cross-sectional and retrospective study design. Chronic lung diseases
identified were chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis and restrictive lung
diseases. Studies were categorised as: (i) community-based, (ii) hospital-based and (iii) comorbidity-related and
disease burden. Reported disease prevalence varied widely (COPD, 1.67–14.3%; asthma, 4.2–8.9%). The
prevalence of airflow obstruction was higher among rural dwellers (15.8%) and those exposed to
household air pollution from domestic biomass burning as opposed to liquid petroleum gas users (Odds
Ratio: 2.06). Several comorbidities, including hypertension and diabetes mellitus added to the disease
burden. The review shows limited literature on lung disease burden in Nepal. Publications varied in terms
of overall quality. Good quality research studies with prospective cohorts related to respiratory conditions are
required.
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Introduction
The burden of chronic lung disease worldwide is
huge, both in terms of morbidity and mortality. It
is increasing and the current COVID-19 pandemic is
likely to add further. Just one lung non-communicable
disease (NCD), chronic obstructive pulmonary disease
(COPD), causes >3 million deaths per year
globally, >90% of these occurring in low to middle-
income countries (LMICs).1,2 Globally identified risk
factors in LMICs include tobacco smoke, household and
ambient air pollution, and occupational exposure.3–8
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The risk factors for developing chronic lung diseases
will vary from country to country. The Himalayas con-
tain several LMICs, many of which share geographical
and cultural features. We chose Nepal as an exemplar
Himalayan LMIC, with a population of circa 30 million
and the 16th poorest country worldwide. Figures on
disease prevalence for Nepal have been reported as part
of the Global Burden of Disease project, these are pri-
marily based on modelled data and are therefore depen-
dent upon broad assumptions that may lack accuracy.9
Reportedly, NCDs in Nepal account for 66% of mortal-
ity, of which chronic respiratory diseases are ranked as
the second highest cause of death (10%), alongside car-
diovascular diseases (30%) and cancer (9%).10 The
gravity of chronic respiratory diseases in Nepal was
highlighted recently, with estimates second worse only
to Kazakhstan for global mortality (Kazakhstan: 114.28
versus 100.75 deaths in Nepal per 100,000).11,12
Respiratory disease greatly impacts health service
demand in Nepal through hospitalisations.13–15
According to the 2016–2017 Department of Health
services in Nepal, bronchial asthma and COPD were
the second and third most common causes of outpa-
tient department morbidity, with cardiovascular con-
ditions as the leading cause.12 Many patients reported
having more than one long-term health condition.
Within Nepal, risk factors for chronic respiratory
diseases vary according to gender and geographical
location. Over 80% of the population lives in rural
settings where a large proportion uses biomass as a
source for heating and cooking fuel within poorly
ventilated living quarters, with exposure to high levels
of household air pollution.16,17 As women generally
do the cooking, this disproportionately affects them.
Smoking is common, particularly in men (27% vs 6%
in women) and in urban areas (30% of households); in
addition, there is significant ambient, agricultural, and
industrial pollution.17–20 These exposures do not only
affect respiratory disease but also contribute to other
health complications and socioeconomic burdens.6,21
The remoteness of some rural locations hinders
alternative energy sources and restricts fuel choices.
Other socio-demographic factors, including illiteracy,
poverty, distance and remote access to healthcare
facilities, also have an adverse impact on health.8,22
The government of Nepal has begun taking
action with policies including the development of
the Integrated NCDs Prevention and Control Policy
of Nepal and the Multisectoral Action Plan for the
Prevention and Control of Non-Communicable Dis-
eases (2014–2020).23 However, innovative health
systemic structures and a comprehensive under-
standing of the burden of diseases are required for
effective implementation.24 This systematic review
aims to synthesise the current available evidence
across community and hospital settings on the pre-
valence of chronic respiratory disease (excluding
cancer), respiratory symptoms, lung function and
lung-related burden in Nepal.
Methods
Search strategy
Initial scoping in May 2019 through MEDLINE,
Embase, Cochrane library and manually, identified
no existing systematic reviews on this area.
The protocol was registered with PROSPERO
(CRD42019138552).25 Database searches were con-
ducted in June 2019 and updated in May 2020 for
publications, with no date restrictions. Nine electronic
databases were searched: Ovid (MEDLINE, Embase,
Global Health, CAB Abstracts), CINAHL, Scopus,
Web of Science, Cochrane Library and Nepal Journal
Online (NEPJOL). Grey literature searches were con-
ducted, including Nepal Government/Health Ministry
reports, World Health Organisation (WHO) data and
OpenGrey. Searches were supplemented by contact
with study authors where additional information was
required as well as forward and backward citation
tracking from included studies. A sample search strat-
egy is shown, Appendix 1.
Study screening and selection
Study designs reporting quantitative population-level
prevalence or incidence of chronic respiratory disease,
lung function, respiratory symptoms or burden of lung
disease in adults (individuals aged 16 years and older)
living in Nepal were considered. The review included
only peer reviewed publications, but grey literature set
the scene in the introduction. Language was not an
exclusion criterion. For this review, publications
studying specific occupational exposure were
excluded. Conference abstracts were excluded follow-
ing screening for full-text peer-reviewed publications.
Study records identified were exported into
Mendeley (London, UK), with duplicates removed.
Titles and abstracts were screened by two indepen-
dent reviewers (WE, CEB). Full texts of potentially
eligible papers were retrieved and assessed indepen-
dently by two reviewers with discrepancies resolved
through discussion. The Preferred Reporting Items for
2 Chronic Respiratory Disease
Systematic Reviews and Meta-Analyses (PRISMA)26
flow diagram of the search and screening process is
shown in Figure 1.
Data extraction and quality assessment
A standardised data extraction form was used for the
final selection of studies. Data were extracted by one
reviewer and checked for accuracy by a second
reviewer. Quality of the included studies was inde-
pendently assessed by two researchers from WE, ARJ
and CEB using the AXIS critical appraisal checklist
for cross-sectional studies.27 In keeping with the
AXIS method, the quality is not judged as a numerical
scoring of the component parts and therefore has a
subjective element.
Data synthesis
Studies were highly heterogeneous with huge variation
used for data acquisition, analysis and reporting.
Therefore the pre-planned meta-analysis was not
possible (see PROSPERO: CRD42019138552), and
the findings were synthesised narratively.28 Early on,
it became apparent that the review would be in three
distinct sections, given the heterogeneity of sites in the
manuscripts: i) community setting, ii) hospital (mostly
inpatients) setting and then iii) comorbidity-related
and lung-related burden of disease.
Results
Study selection
A total of 6,393 papers were identified. Followng
removal of duplicates, 4,252 studies were screened by
titles and abstracts, and 121 full-text studies reviewed
(Figure 1), with 27 articles included (Tables 1–3).
Overview of included studies
Years of publication ranged from 1984 to 2019, and
all were published in English. One was published in
Figure 1. PRISMA flow chart of included studies.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the 1980s,29 7 between 2000 and 2010,30–36 and 19 after
2011.20,37–54 All included studies were cross-sectional,
direct observations of clinical notes, comparative and
single point survey designs.20,29–54 The studies reported
on diseases (usually self-reported), symptoms, related
health conditions and lung function. Most of the studies
were either of low (n¼ 13) or moderate (n¼ 12) quality,
with two classed as high quality.
Some studies reported on more than one condi-
tion, with the major diseases identified being:
COPD (22 studies),31,32,34–36,38–54 asthma (8 stud-
ies),20,32,36,37,49,52–54 bronchiectasis (2 studies and
as a co-morbidity in one),30,40,52 restrictive lung
diseases (3 studies),49,51,52 and ‘chronic bronchitis’
(1 study).29
Symptoms reported included chronic cough,
phlegm or sputum production, breathlessness or
shortness of breath, chest tightness, wheezing, dys-
pnoea and sore throat. Reporting included presence
of pulmonary arterial hypertension30 and cor
pulmonale.29,30,35,51,52
Lung function was reported in seven stud-
ies,29,32,33,38,47,48,51 and data presented across differ-
ent spirometric measures, with one reporting
proportions only of patients categorised as ‘normal’,
‘obstruction’ and ‘restriction’.51
Community-based prevalence studies
Studies included over 18,000 participants across diverse
population groups (Table 1). COPD and asthma, (usu-
ally self-reported), were covered across small-medium
sized studies of 78 to 401 participants,20,32,36–38 with
one large-scale study of 12,557 participants (prevalence
determined in 11,277).50 A study of chronic bronchitis,
according to the Medical Research Council definition,
was based on 2,826 participants.29
One study on both rural and urban households
reported a COPD prevalence of 14.3%.36 This was
comparable with the findings of Dhimal et al.,50
which reported a nationwide prevalence of COPD of
11.7%. These findings differed from other studies,
where reported COPD prevalence was 1.67% in rural
adult kitchen dwellers (reported in the paper as adults
who spend a large amount of the day in the kitchen),32
and 6% COPD prevalence in rural community resi-
dents using biomass fuels.38 Meanwhile, prevalence
of chronic bronchitis of 18.3% was reported in a study
with an additional 3.1% with emphysema too.29
Asthma prevalence ranged from 4.2% to 8.9%20,32,36
but one study reported 25.4% in adults 60 years.37
Generally, chronic respiratory diseases were more
prevalent in adults aged over 40 years.37,38,50
In a general representative population, symptom-
wise, one study reported cough, phlegm, breathless-
ness and wheezing to each have a prevalence of over
20%, and greater among populations using unpro-
cessed fuels and living in rural regions, than in those
using processed fuels and living in urban house-
holds.36 This agreed with Ranabhat et al.,20 where
reported breathlessness and productive cough were
27.3% and 19.7% of individuals living in rural com-
munities exposed to household air pollution. Kurmi
et al.47 reported that wheeze (male, 23.5% vs 8.7%;
female, 32% vs 10.3%) and dyspnoea (male, 12% vs
2.5%; female, 17.8% vs 7.6%) were more prevalent
symptoms in the rural environment as a whole,
whereas chronic phlegm (male, 4.7% vs 5.3%;
female, 4.4% vs 4.2%) and cough (male, 3% vs
12.9%; female, 4% vs 5.8%) were more comparable
between rural and urban environments.48 Symptom
reporting was also greater in current and past smokers
than never smokers, with the prevalence of cough,
phlegm, breathlessness and wheezing all above 11%
in rural community kitchen dwellers as a whole.32
Kurmi et al.,47,48 a large study, reported across two
publications that the odds ratio of having airflow
obstruction with exposure to biomass was two times
higher (OR: 2.06)47,48 compared to liquid petroleum
gas users. Males (OR: 1.94; p ¼ 0.035) were more at
risk of suffering airflow obstruction after exposure to
biomass (OR: 1.30; p ¼ 0.436) when the threshold of
FEV1/FVC < 0.70 was utilised but not for a threshold
of FEV1/FVC < lower limit of normal (Males, OR:
1.11, p ¼ 0.840; Females, OR: 1.67, p ¼ 0.281). Air-
flow obstruction was reported in 15.8% of rural com-
munity residents using a subset representative of the
overall study population, with airflow obstruction pre-
valent in 57.4% among those meeting the study criteria
for chronic bronchitis.29 Smokers had lower lung func-
tion in one study compared to those who reported to not
smoke, although it was unclear whether this compara-
tor group were ex- or never smokers33. Pratali et al.38
found that 54% of rural community residents using
biomass fuels had a FEF25–75 < 80% predicted. Joshi
et al.32 reported absolute peak flow and not % pre-
dicted, and therefore is largely uninterpretable.
Hospital-based studies
Ten studies, including a total of 111,188 subjects
reported on the prevalence of chronic respiratory
Ekezie et al. 13
diseases in a hospital setting (Table 2).31,34,42–45,49,51,53,54
The majority of studies reported on COPD among
hospitalised patients,31,34,42–45 with other studies
reporting on interstitial lung disease (ILD),51 both
COPD and asthma,53,54 and outpatient spirometry
referrals.49
Overall estimates for the proportion of admissions
due to COPD varied widely from 2.6% to 14% in
studies including all hospital admissions and up to
17.3% in medical wards.31,42,43,45 Two studies
reported that among hospitalised participants with
an NCD, 43–45% were COPD patients.42,43 In two
studies, the majority of hospitalised COPD patients
were females (60%).42,44
One study reporting on dyspnoea admissions (this
being 9% of all the admissions) at one hospital, iden-
tified that 52.3% received a respiratory diagnosis for
that presentation, another 13% had a combined
respiratory and cardiovascular cause, and 9.3%
received a diagnosis of respiratory accompanied with
other complications.54 However, dyspnoea was also
due to metabolic (11.2%), neuropsychiatric (6.7%)
and cardiovascular alone (3.7%).54 In a study where
the majority of hospital admissions were attributed to
injuries in young adults, respiratory complaints still
accounted for 9.2% of total hospital admissions, with
COPD or asthma accounting for 0.5% of total hospital
admissions.53
Ghimire et al.51 reported a prevalence of 0.4% for
ILD among patients treated in hospital for pulmonary
disorders. The majority of these ILD’s were attributed
to idiopathic pulmonary fibrosis (79.5%), and 68.1%
of the patients were over the age of 60 years.51
There was only one hospital-based study with spiro-
metry for outpatients: the final diagnoses being bron-
chial asthma (24.2%), COPD (31.4%), and restrictive
lung disease (8.1%) of those referred for testing.49
Comorbidity-related and burden of disease
Eleven studies, with a total of 96,594 patients
reported on comorbidity and burden of chronic
respiratory disease.30,31,35,39–41,45,46,51–53 The major
chronic respiratory diseases were COPD (seven
studies),31,35,39–41,45,46 bronchiectasis (one study),30
ILD (one study),51 COPD or asthma (one study),53 or
they assessed COPD, asthma, bronchiectasis and ILD
together (one study) (Table 3).52 Reported comorbid-
ities covered other respiratory conditions, endocrine,
cardiovascular disease, sleep and mental health
disorders.
Common comorbidities reported in patients with
COPD were hypertension ranging 9.9–41.3% of
subjects,31,35,39 diabetes mellitus: 3.7–5%,31,35,39
ischaemic heart disease/coronary artery disease:
1.6–10%,31,35,39 dilated cardiomyopathy: 2.4–4%,31,35
chronic cor pulmonale: 27.3%,35 and type II respiratory
failure: 10.4%.35 One study in patients with COPD who
had echocardiography reported that all had echocardio-
graphy evidence of pulmonary hypertension, of which
60% were severe.46 Another study reported a co-morbid
presence of bronchiectasis in 44% of COPD patients.40
Anxiety and depression were almost three times more
common in COPD patients compared to the general
population.41
One study reported that patients with an initial
diagnosis of ILD had a 45.4% prevalence of
gastro-oesophageal reflux disease, 15.9% diabetes
mellitus, 15.9% hypertension, 13.6% cor pulmonale,
11.4% renal impairment, and 9.1% ischaemic heart
disease.51 Systemic hypertension (36%), diabetes
mellitus (16%), metabolic syndrome (24%), ischae-
mic heart disease (6%) and heart failure (6%) were
prevalent across multiple chronic respiratory diseases
(COPD, ILD, bronchiectasis and asthma).52 Two
studies reported on sleep disorders with Ghimire
et al.51 reporting obstructive sleep apnoea prevalence
in 4.5% of ILD patients, while Koirala et al.52
reported that 62.5% of COPD and 55.6% of asthma
patients had sleep-related breathing disorders.
Two studies reported mortality rates ranging from
6–20% in patients admitted to hospital with
COPD.39,45 Another study reported a 90-day mortality
rate of 32% for patients admitted to the hospital with
any complication with an accompanying diagnosis of
COPD or asthma.53 The prevalence of an exacerba-
tion requiring hospitalisation was nearly double in
COPD patients with coexistent bronchiectasis com-
pared to those without (56.6% vs 26.8%).40 Ghimire
et al.51 reported survival rates of 95% at 5 months,
84% 1-year, and 42% 2-year following ILD diagnosis.
In patients with bronchiectasis or ILD, common
symptoms experienced included cough (bronchiecta-
sis, 100%; ILD, 97.7%), haemoptysis (bronchiectasis,
75%; ILD, 4.5%), worsening shortness of breath
(bronchiectasis, 70%; ILD, 95.5%), and fever
(bronchiectasis, 50%; ILD, 34.1%).30,51
Discussion
This study has identified and synthesised the available
evidence on the prevalence of chronic respiratory
14 Chronic Respiratory Disease
diseases, symptoms, lung function, comorbidities and
the overall burden of lung disease in Nepal. Overall,
COPD is common, both in males and females, and is
associated with frequent hospital admission and a
range of comorbidities. Smoking and household air
pollution were found to be common risk factors. Esti-
mates of asthma prevalence varied widely and there
was no good data on the ILD prevalence.
Community-based findings
The findings highlight the high prevalence of COPD
and the varied prevalence of asthma in Nepal. The
global prevalence of COPD has been reported to be
approximately 9.2%,55 with other estimates suggest-
ing age-standardised figures for prevalence of males:
3.2% and females: 2.0%.56 In comparison, large-scale
and high quality studies assessing COPD prevalence
in representative samples of the overall population in
LMIC’s such as China and India have shown preva-
lence to be 8.6%57,58 and 4.2% respectively.59 The
prevalence estimates of 1.67% to 14.3% in Nepal vary
significantly on either side of these prevalence fig-
ures, making it challenging to draw meaningful com-
parisons. As with COPD, asthma prevalence figures
for Nepal varied widely depending on the population,
rendering it difficult to interpret alongside World
Health Surveys and findings from other LMICs where
prevalence of diagnosed asthma have been estimated
at 4.3%60 and 2.9% respectively.59 However, both
asthma and COPD prevalence figures could be
impacted by the misclassification of disease and by
the lack of quality studies. To date, most publications
reporting COPD diagnosis in Nepal are not based on
spirometry, and where they are, they did not assess
post-bronchodilator measurements.61 Similarly, the
term ‘COPD’ is not universally recognised in Nepal,
and therefore there is further misclassification of
patients as having asthma or other terms for chronic
lung disease. This review highlights that the large
proportion of the prevalence studies were of moderate
to low-quality evidence and utilised diverse popula-
tions and approaches.
Two publications from the same large project met
the criteria for high quality.47,48 The use of biomass
fuels as a household energy source markedly
increased the risk of airflow obstruction compared
to liquefied petroleum,47 in line with the Global
Burden of Disease study and other studies.62–65
Further, symptoms are prevalent in both urban and
rural community dwellers, but particularly in rural,
where there is greater use of biomass fuels leading
to household air pollution.48 These observations agree
with previous findings.66,67 However, some recent
evidence contradicts the lung function observations,
whereby post-bronchodilator airflow obstruction was
not associated with the use of biomass fuels.68
Hospital-based findings
In the hospital setting, the estimates of COPD and
asthma also varied across studies. The reporting of
hospital admissions attributed to COPD and/or
asthma in Asian LMICs is scarce in the literature
providing challenges in making effective compari-
sons. Of the available evidence, a study looking into
hospital admission causes in China reported that
chronic respiratory disease contributed to 22.6% of
total admissions.69 Dagenais et al.70 further suggested
that respiratory disease patients accounted for around
8.5% of global hospital admissions, but the number of
first admissions attributed to respiratory disease was
higher (4.9%) in high income countries compared to
LMIC (1.9%). It was suggested that this was due to
higher diagnosis rates and earlier treatment in high
income countries. 70
Of note, two studies highlighted that most hospita-
lised COPD patients were female.42,44 This conflicts
evidence from other LMICs whereby hospital admis-
sions for COPD appear to be more males,71,72 and
prevalence rates of COPD are higher in males.58,73
This finding is of potential importance in addressing
the burden of COPD in Nepal and needs to be inves-
tigated further. One possibility is the greater exposure
of women to household air pollution.
It is important to note that drawing comparisons
with other countries based on the low to moderate
quality data are hindered by the disparities in report-
ing of admissions, including whether total hospital
admissions, select age groups or select hospital
departments and also the hospital location and access.
All these factors hinder interpretation, especially
when the studies tend to include large hospital centres
in urban areas. This creates challenges in providing
evidence relating to rural environments.
Comorbidity-related and burden findings
A high prevalence of concurrent comorbidities
included other respiratory disorders, 35,40,51,52 cardio-
vascular disease,31,35,39,46,51,52 diabetes,31,35,39,51,52
anxiety and depression.41 The estimates of prevalence
varied markedly. Although these were small and
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discrete populations, the coexistent comorbidities con-
cur with the literature in other countries and warrant
further investigation and studies to delineate the addi-
tive burden, contribution to mortality, opportunity for
earlier identification and prevention.74,75
There was minimal literature on mortality associ-
ated with chronic respiratory disease. For COPD,
in-hospital mortality rates ranged from 6–20%,39,45
which is a wide variation in the estimate. Compari-
sons may be drawn with COPD in-hospital mortality
rates in India, which are around 12%,72 but further
clarity is needed to distinguish a precise estimate in
Nepal. Access to hospital and possible later presenta-
tion with symptoms, healthcare costs and the provi-
sion and access of core medications and treatment
once at the hospital are factors. There was no
population-level COPD or other chronic lung disease
mortality data for Nepal.
Strengths and limitations
This review included self-reported and diagnosed
lung disease, symptoms, lung function and comorbid-
ity, allowing capture on the wider burden of respira-
tory disease. Outcomes needed to be contextualised to
study setting, allowing for adequate reflection for
future research and policy utilisation and a rounded
view of respiratory disease burden in both the com-
munity and hospital while highlighting variation and a
need for further research.
The main limitation was the considerable hetero-
geneity in the studies in terms of population sampling
approach and data collection methods leading to a
variety of outcome measures and a range of informa-
tion. There were stark differences in study quality
stemming from design and setting, which make it
necessary to separate the study into three categories.
The populations recruited to these studies should also
be considered with several elements identified that
infer heavy bias, potentially affecting the interpreta-
tion of results. For example, lack of segregated data
based on the age of the population monitored meaning
standardised results could not be produced, lack of
spirometry especially including post-bronchodilator
assessments to determine the overall prevalence, lack
of reporting on medications, lifestyle factors, previous
medical history (e.g. childhood respiratory complica-
tions), and socioeconomic status to help interpret the
populations included. It is also important to note that
no data on incidence of chronic respiratory diseases
were available for reporting, and that reported
symptom data were not consistent. As a result, the
high variability required a narrative analysis approach
with details of the population presented as opposed
to a pooled estimate of prevalence and burden. Ulti-
mately, these issues made it difficult to compare stud-
ies but have helped to provide an evidence base for
future research needs assessing non-communicable
lung disease burden in Nepal.
Implications for future health research and care
While unable to fully delineate the estimates of the
true prevalence of respiratory disease in Nepal, the
scale and burden of chronic lung disease are marked.
Current research is taking a population approach to
systematically identify the scale of COPD in urban
Nepal.76 Identifying the estimates and burden of
disease drives the need for optimised healthcare stra-
tegies and subsequent implementation and dissemina-
tion. For example, smoking cessation to reduce
tobacco exposure77–79 and pulmonary rehabilitation77
have a strong evidence base in their effectiveness in
managing lung diseases. Pulmonary rehabilitation
takes a holistic approach to reduce breathlessness,
improve function and treat multimorbidity.80 Impor-
tantly, these are high value, low-cost interventions
and will be of an increasing need for a country with
an increasing life expectancy and a growing issue of
NCD prevalence. Reducing exposures through smok-
ing cessation and utilisation of alternative fuel sources
alongside health promotion are key to the long-term
management and prevention of chronic respiratory
diseases in Nepal. However, any consideration and
inclusion of public health interventions needs a full
evaluation of their potential appropriateness and
acceptability given the tremendous social, cultural,
linguistic, economic and geographic diversity of
Nepal. Important factors include the fact that a large
proportion of people in Nepal live in very rural and
often mountainous terrain, many are living in extreme
poverty and illiteracy is high.8,16,17,22
Conclusion
This systematic review demonstrated that there is lim-
ited published literature on the burden of lung disease
and marked variation in outcome measures and popu-
lations studied. Nonetheless, chronic respiratory bur-
den in Nepal is likely to be considerable. This is a
priority area for future research. Based on the avail-
able information, there is a clear need for further
studies and the need for healthcare professionals,
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providers and policymakers to develop effective stra-
tegies to tackle chronic respiratory diseases in Nepal.
These findings are also likely to be relevant to other
Himalayan LMICs.
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Appendix 1
Search strategy from Scopus
(Nepal AND asthma) OR (Nepal AND bronchiectasis)
OR (Nepal AND chronic bronchitis) OR (Nepal AND
chronic obstructive pulmonary disease*) OR (Nepal
AND emphysema) OR (Nepal AND idiopathic pul-
monary fibrosis) OR (Nepal AND lung fibrosis) OR
(Nepal AND interstitial lung disease*) OR (Nepal
AND silicosis) OR (Nepal AND occupational lung
disease*) OR (Nepal AND small airways disease*)
OR (Nepal AND breathless*) OR (Nepal AND
cough*) OR (Nepal AND wheez*) OR (Nepal AND
dyspn*) OR (Nepal AND respiratory arrest*) OR
(Nepal AND exacerbat*) OR (Nepal AND hypoxemia)
OR (Nepal AND sputum) OR (Nepal AND phlegm)
AND (LIMIT-TO (DOCTYPE,“ar”) OR LIMIT-TO
(DOCTYPE,“cp”)) AND (LIMIT-TO (EXACTKEY
WORD,“Human”)) AND (LIMIT-TO (SUBJAREA,
“MEDI”) OR LIMIT-TO (SUBJAREA,“PHAR”) OR
LIMIT-TO (SUBJAREA, “AGRI”) OR LIMIT-TO
(SUBJAREA,“ENVI”) OR LIMIT-TO (SUBJAREA,
“SOCI”) OR LIMIT-TO (SUBJAREA,“NURS”) OR
LIMIT-TO (SUBJAREA,“HEAL”))
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